Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 16:28 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies
NCT03277352 · Incyte Biosciences International Sàrl · PHASE1/PHASE2 · terminated · last registry update 2021-07-22 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “The study was terminated due to emergent data from another study and unrelated to safety.” | – | Registry record, Incyte Biosciences International Sàrl |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against TNFRSF18 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
No results, stops or Phase 3 starts on the same target in that window.
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision